Format

Send to

Choose Destination
J Med Food. 2013 Mar;16(3):211-5. doi: 10.1089/jmf.2012.0069. Epub 2013 Feb 27.

Effect of emulin on blood glucose in type 2 diabetics.

Author information

1
ATM Metabolics LLC, Winter Haven, FL 33884, USA. j.ahrens@atmmetabolics.com

Abstract

Emulin™ is a patented blend of chlorogenic acid, myricetin, and quercetin that has shown efficacy in reducing midday and post-oral glucose tolerance test (OGTT) area under the curve (AUC) glucose in streptozotocin-treated rats. The purpose of this study was to determine if similar effects would be evident in type 2 diabetic humans. Forty human subjects with confirmed type 2 diabetes (10 each in 4 groups: placebo/no medication, Emulin/no medication, placebo/metformin and Emulin/metformin) were evaluated. At the end of 1 week, fasting blood glucose, 2 h postprandial, actual peak glucose, and AUC (post-50 g OGTT) were determined. The placebo-only group had a large (5%-13%) increase in all parameters. The Emulin group and those on metformin performed similarly with reductions between 1% and 5%, with Emulin slightly outperforming the medication-alone group. The most significant reduction occurred in the Emulin/metformin group, with decreases in the parameters by up to 20%. These results suggest that Emulin, if consumed regularly, could not only have the acute effect of lowering the glycemic impact of foods, but chronically lower background blood glucose levels of type 2 diabetics.

PMID:
23444965
DOI:
10.1089/jmf.2012.0069
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center